Loading clinical trials...
Loading clinical trials...
Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.
After emergence of a new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2) responsible for a cluster of respiratory infection at Wuhan, China, on January, 7th 2020, first cases were diagnosed in France in January 24th 2020. Health care components of Samusocial de Paris (Lits Haltes Soins Santé (LHSS)) were created in 2006. They provide medical care for homeless people and people in social distress not needing an hospitalization. Sometimes there are 3 persons in a bedroom. In december 2018, a special shelter for isolated women or women in precarious situations opened. Because of the living conditions in these centers and the difficulty for these populations to respect social distancing and hygiene recommendations. A first case of COVID-19 was identified on March 8th 2020 in one of these healthcare centers. Other cases were detected in the same center, then in another center on March 16th, then in the dormitory of the women shelter on March 30th. A recent study showed an important prevalence of SARS-COV2 in residents of a homeless shelter in Boston (36%), most of them were asymptomatic. Seroprevalence studies are done in general population or in health care workers, but don't include vulnerable people. It seemed important to us to describe the epidemic in these centers and to study COVID-19 seroprevalence in these particular populations.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Haltes pour femmes
Paris, France
LHSS Saint-Michel
Paris, France
LHSS Ridder-Plaisance
Paris, France
Start Date
July 22, 2020
Primary Completion Date
April 8, 2021
Completion Date
August 22, 2021
Last Updated
January 26, 2026
179
ACTUAL participants
blood test for SARS-COV2 serology
DIAGNOSTIC_TEST
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators
NCT05115617
NCT04896866
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions